Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
Taylor C. Duke, MD,
Ranjit Nair, MD,
Carlos Torres-Cabala, MD,
Rodabe N. Amaria, MD,
Elizabeth Keiser, MD,
Roberto Miranda, MD,
Swaminathan P. Iyer, MD,
Meghan Heberton, MD
Affiliations
Taylor C. Duke, MD
Department of Dermatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas
Ranjit Nair, MD
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Carlos Torres-Cabala, MD
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Rodabe N. Amaria, MD
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Elizabeth Keiser, MD
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Roberto Miranda, MD
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Swaminathan P. Iyer, MD
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Meghan Heberton, MD
Department of Dermatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Correspondence to: Meghan Heberton, MD, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030.
